Last year, we took several important steps to progress toward equity, racial justice, diversity, and inclusion and better understand the challenges that Black, Hispanic, and other people of color with CF and their families face. These principles will continue to be a cornerstone of our work, and we will not rest until all people with cystic fibrosis can live long, fulfilling lives.

Read highlights from 2022 »

We announced last week that we are investing up to $3.5 million in Gensaic Inc. to conduct preclinical research to develop a novel approach to deliver a gene therapy to the lung cells of people with cystic fibrosis. If successful, this gene delivery vehicle would deliver a healthy cystic fibrosis transmembrane conductance regulator (CFTR) gene to lung cells, which would enable the production of functioning CFTR protein.  

Read the Gensaic announcement »

In addition, we awarded up to $15 million to ReCode Therapeutics for preclinical research and early-stage clinical trials for their mRNA therapy, which could eventually provide a treatment option for all people with cystic fibrosis, regardless of their mutations.  

Read the ReCode announcement »

The CF Foundation is extending their support for free access to Beam, an online exercise, education, and well-being platform. People with CF ages 18 and older in the United States can continue to enjoy a variety of on-demand and live classes at no cost through June 2023. No promo code necessary.

Join Beam today »

Residential households in the U.S. are now eligible for another order of free at-home COVID-19 tests from USPS. Each order includes four rapid antigen COVID-19 tests. 

Order COVID-19 tests »